Want to see AU:RHY full AI Analyst Report?
RHY Stock Chart & Stats
AU$0.10
-AU$0.01(-11.11%)
At close: 4:00 PM EDT
AU$0.10
-AU$0.01(-11.11%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.28
Previous CloseN/A
Volume360.17K
Average Volume (3M)221.58K
Market Cap
AU$29.85M
Enterprise ValueAU$28.21
Total Cash (Recent Filing)AU$3.44M
Total Debt (Recent Filing)AU$247.98K
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding364,059,840
10 Day Avg. Volume229,995
30 Day Avg. Volume221,576
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)8.36
Price to Sales (P/S)356.41
P/FCF Ratio-5.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow debt and positive equity provide a comparatively resilient balance-sheet foundation for a development-stage diagnostics company. This reduces immediate leverage pressure and preserves some flexibility to support operations, although ongoing losses could still erode the capital base over time.
Focused Diagnostic Product StrategyA focused IVD strategy centered on ColoSTAT gives the company a defined product direction and a clear clinical application in colorectal cancer screening. If development and commercialisation progress, this concentration may help direct limited resources toward a potentially scalable diagnostic offering.
Demonstrated Revenue PotentialThe ability to generate substantially higher revenue in FY2025 indicates that the business has shown some capacity to produce commercial activity at a greater scale than its weakest periods. That provides evidence of potential, even though revenue has not yet become consistent or profitable.
Bears Say
Persistent UnprofitabilityRecurring losses across the reported periods show that the business has not yet established a sustainable earnings model. Continued negative EBIT, EBITDA, and net income can constrain reinvestment, weaken the capital base, and increase dependence on future funding while development continues.
Persistent Cash BurnConsistently negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. The sizable FY2026 burn could require continued use of reserves or external funding, limiting financial flexibility and increasing execution pressure.
Unstable And Declining RevenueThe sharp FY2026 revenue decline after strong FY2025 growth demonstrates that commercial performance remains volatile rather than established. Revenue at very low scale also produced materially negative gross profit, indicating weak cost absorption and limited evidence of durable operating leverage.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.07 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$29.85M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 148 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.011 earnings per share for the quarter.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.011 in its last earnings report. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:RHY Sentiment 50%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Microba Life Sciences Limited
―